Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Huiqin Lai"'
Autor:
Zhanpeng Liang, Liwen Liu, Wenxia Li, Huiqin Lai, Luzhen Li, Jiaming Wu, Huatang Zhang, Cantu Fang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveZolbetuximab is a “first-in-class” chimeric lgG1 monoclonal antibody targeting Claudin18.2 (CLDN 18.2). In recent years, several important trials have been published showing that zolbetuximab is associated with improved prognosis in pati
Externí odkaz:
https://doaj.org/article/ee5f0b5ec11745d7ad4fb1eff4ccdd47
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundThe addition of endocrine therapy to salvage radiotherapy (SRT) is expected to further improve the prognosis of patients with biochemical recurrence of prostate cancer after radical prostatectomy (RP). The quantitative synthesis of clinical
Externí odkaz:
https://doaj.org/article/1eff0b3d50054c479b3ad4239052b7fc
Autor:
Luzhen Li, MM, Ting Chen, MM, Huiqin Lai, BD, Ao Zhang, BD, Xianhui Zhao, MM, Jiaming Wu, MM, Huisi Hong, Lexia Wu, BD, Sihong Lin, BD, Kexin Wang, LP, Huatang Zhang, BD, Cantu Fang, BD
Publikováno v:
Medicine, Vol 101, Iss 23, p e29336 (2022)
Abstract. Rationale:. For locally advanced non-small cell lung cancer (NSCLC), the neoadjuvant therapy strategy of preoperative nivolumab combined with chemotherapy has great potential, especially for locally advanced NSCLC which are initially unrese
Externí odkaz:
https://doaj.org/article/d81293d84ff840c5b96e977fcbd9f48e
Autor:
Zhanpeng Liang, Liwen Liu, Wenxia Li, Huiqin Lai, Luzhen Li, Jiaming Wu, Huatang Zhang, Cantu Fang
Publikováno v:
Frontiers in Oncology; 2023, p1-11, 11p